PFKFB3 and metabolic dysfunction-associated steatotic liver disease: Importantly, SGLT2i suppresses glycolysis by downregulating PFKFB3, thereby triggering intracellular metabolic reprogramming and inducing phenotypic transformation of macrophages, which is one of the important mechanisms of SGLT2i in improving NAFLD.